With Covid death rates plunging in 2022, vaccine advocates hav | Alex Berenson

With Covid death rates plunging in 2022, vaccine advocates have tried to give the mRNA jabs the credit, claiming endlessly that the shots reduce deaths and severe outcomes even after they stop working against disease.

But considerable circumstantial evidence - both epidemiologic and cellular - suggests otherwise. Among the most important points:

Deaths have fallen even faster in countries that did NOT use the mRNA jabs;

In most mRNA countries, deaths are now overwhelmingly in the vaccinated;

Highly mRNA vaccinated countries that did not have earlier Covid waves, such as Australia and New Zealand, have had some of the highest death rates this year, suggesting that immunity from earlier infections rather than the shots is crucial to reducing deaths;

Studies of cellular-level immunity suggest that the mRNA shots do not build T-cell immunity against Omicron - which is the major theoretical reason they might reduce deaths even after they fail against infections.

Now this paper builds on the evidence that Paxlovid - which has been given to millions of Covid patients around the world - is playing an important role in the drop in deaths this year.

And who makes and sells Paxlovid? Pfizer, of course!

Yes, the same company that has sold tens of billions of dollars in mRNA vaccines that do little against Omicron and may actually increase the risk of infection with new variants over time. Now it’s now selling tens of billions of dollars in an anti-viral pill that - for now - does seem to work against every variant. Further, Paxlovid is likely to add to Pfizer’s profits for years, even as demand for the vaccines collapses.

Albert Bourla, Pfizer’s chief executive, may no longer be the world’s favorite veterinarian - as the hammering he took last week after announcing on Twitter he had Covid suggested.

But Paxlovid’s success suggests that he remains a very, very lucky man. (4/4)